Latest Peplin news

news

09-June-09

Peplin Initiates Phase 3 Clinical Trials with PEP005 Gel in AK on Face and Scalp read more

28-May-09

Peplin's Positive Phase II AK Trial Results Published in JAAD read more

17-May-09

Positive Results for Peplin's First Phase III AK Trial read more

15-May-09

Peplin Results for the Quarter Ended 31 March 2009 read more

›› More News

API Manufacturing

Peplin owns and operates a GMP licensed, commercial-scale manufacturing facility located in Southport, Queensland, Australia for API production of our proprietary, lead compound PEP005 (ingenol mebutate), a well characterized and purified single molecular entity sourced from a rapidly growing plant called Euphorbia peplus. The entire production process involves cultivation, post-harvest processing, GMP extraction, purification and formulation of PEP005 using strict quality standards for use in clinical trials.

Various contractors based in southeast Queensland and internationally support these activities.